Foundation Medicine Company Profile (NASDAQ:FMI)

About Foundation Medicine (NASDAQ:FMI)

Foundation Medicine logoFoundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer. Its suite of clinical molecular information products includes FoundationOne, which is used for solid tumors; FoundationOne Heme, which is used for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma, pediatric cancers and advanced sarcoma; FoundationACT (Assay for Circulating Tumor DNA), which is a blood-based (liquid biopsy) assay that evaluates circulating tumor deoxyribonucleic acid (ctDNA), and FoundationFocus CDxBRCA, which is a companion diagnostic assay to aid in identifying women with ovarian cancer for whom treatment with Rubraca (rucaparib).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FMI
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.42747 billion
  • Outstanding Shares: 35,642,000
Average Prices:
  • 50 Day Moving Avg: $37.92
  • 200 Day Moving Avg: $28.65
  • 52 Week Range: $16.95 - $43.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.18
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $112.82 million
  • Price / Sales: 13.06
  • Book Value: $3.55 per share
  • Price / Book: 11.65
  • EBIDTA: ($125,890,000.00)
  • Net Margins: -126.17%
  • Return on Equity: -80.75%
  • Return on Assets: -64.22%
  • Current Ratio: 3.65%
  • Quick Ratio: 3.35%
  • Average Volume: 225,402 shs.
  • Beta: -0.06
  • Short Ratio: 17.17

Frequently Asked Questions for Foundation Medicine (NASDAQ:FMI)

What is Foundation Medicine's stock symbol?

Foundation Medicine trades on the NASDAQ under the ticker symbol "FMI."

How were Foundation Medicine's earnings last quarter?

Foundation Medicine, Inc. (NASDAQ:FMI) issued its earnings results on Tuesday, May, 9th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.02) by $0.29. The company had revenue of $26.32 million for the quarter, compared to analysts' expectations of $29.07 million. Foundation Medicine had a negative return on equity of 80.75% and a negative net margin of 126.17%. Foundation Medicine's revenue for the quarter was down 13.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.50) earnings per share. View Foundation Medicine's Earnings History.

Where is Foundation Medicine's stock going? Where will Foundation Medicine's stock price be in 2017?

5 analysts have issued 12 month price targets for Foundation Medicine's stock. Their forecasts range from $25.00 to $39.00. On average, they expect Foundation Medicine's share price to reach $31.67 in the next year. View Analyst Ratings for Foundation Medicine.

Who are some of Foundation Medicine's key competitors?

Who are Foundation Medicine's key executives?

Foundation Medicine's management team includes the folowing people:

  • Michael J. Pellini M.D., Chairman of the Board
  • Steven J Kafka Ph.D., President, Chief Operating Officer
  • Troy Cox, Chief Executive Officer, Director
  • Jason Ryan, Chief Financial Officer, Principal Financial Officer, Principal Accounting officer
  • Robert Hesslein, Senior Vice President, General Counsel
  • David J. Daly, Chief Commercial Officer
  • Vincent Miller M.D., Chief Medical Officer
  • Alexis Borisy, Director
  • Michael R. Dougherty, Director
  • Evan Jones, Independent Director

Who owns Foundation Medicine stock?

Foundation Medicine's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (4.55%), Chevy Chase Trust Holdings Inc. (3.10%), Alliancebernstein L.P. (2.23%), Oppenheimer & Co. Inc. (1.90%), Vanguard Group Inc. (1.65%) and Pioneer Investment Management Inc. (0.92%). Company insiders that own Foundation Medicine stock include David Daly, Jason Ryan, Michael J Pellini, Robert W Hesslein, Steven J Kafka and Vincent A Miller. View Institutional Ownership Trends for Foundation Medicine.

Who sold Foundation Medicine stock? Who is selling Foundation Medicine stock?

Foundation Medicine's stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Rockefeller Financial Services Inc., Oppenheimer & Co. Inc., Morgan Stanley, Platinum Investment Management Ltd., SG Americas Securities LLC, Strs Ohio and Goldman Sachs Group Inc.. Company insiders that have sold Foundation Medicine stock in the last year include David Daly, Jason Ryan, Michael J Pellini, Robert W Hesslein and Steven J Kafka. View Insider Buying and Selling for Foundation Medicine.

Who bought Foundation Medicine stock? Who is buying Foundation Medicine stock?

Foundation Medicine's stock was acquired by a variety of institutional investors in the last quarter, including Pioneer Investment Management Inc., Alliancebernstein L.P., Chevy Chase Trust Holdings Inc., Adalta Capital Management LLC, Geode Capital Management LLC, Vanguard Group Inc., EAM Investors LLC and KCG Holdings Inc.. View Insider Buying and Selling for Foundation Medicine.

How do I buy Foundation Medicine stock?

Shares of Foundation Medicine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Foundation Medicine's stock price today?

One share of Foundation Medicine stock can currently be purchased for approximately $41.35.

MarketBeat Community Rating for Foundation Medicine (NASDAQ FMI)
Community Ranking:  1.0 out of 5 ()
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  252
MarketBeat's community ratings are surveys of what our community members think about Foundation Medicine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Foundation Medicine (NASDAQ:FMI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $31.67 (23.42% downside)

Analysts' Ratings History for Foundation Medicine (NASDAQ:FMI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017BTIG ResearchUpgradeNeutral -> Buy$39.00HighView Rating Details
4/3/2017William BlairReiterated RatingBuyLowView Rating Details
3/7/2017Janney Montgomery ScottUpgradeSell -> Neutral$31.00N/AView Rating Details
11/3/2016Benchmark Co.DowngradeBuy -> HoldN/AView Rating Details
8/3/2016J P Morgan Chase & CoReiterated RatingHold$25.00N/AView Rating Details
5/4/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
2/26/2016Goldman Sachs Group, Inc. (The)Lower Price TargetNeutral$17.00 -> $15.00N/AView Rating Details
11/4/2015WedbushLower Price TargetNeutral$26.00 -> $19.00N/AView Rating Details
9/16/2015Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
7/30/2015JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 6/22/2015 forward)


Earnings History for Foundation Medicine (NASDAQ:FMI)
Earnings by Quarter for Foundation Medicine (NASDAQ:FMI)
Earnings History by Quarter for Foundation Medicine (NASDAQ FMI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($1.02)($1.31)$29.07 million$26.32 millionViewListenView Earnings Details
2/22/2017Q416($0.96)($1.02)$29.23 million$28.80 millionViewListenView Earnings Details
11/2/2016Q316($0.88)($0.90)$28.70 million$29.43 millionViewN/AView Earnings Details
8/2/2016Q216($0.79)($0.84)$26.72 million$28.24 millionViewN/AView Earnings Details
5/3/2016Q116($0.72)($0.50)$25.20 million$30.40 millionViewN/AView Earnings Details
2/23/2016Q415($0.67)($0.55)$25.76 million$26.10 millionViewListenView Earnings Details
11/3/2015Q315($0.56)($0.60)$24.04 million$25.40 millionViewListenView Earnings Details
7/29/2015Q215($0.56)($0.98)$24.44 million$22.50 millionViewListenView Earnings Details
5/11/2015Q115($0.53)($0.59)$21.00 million$19.30 millionViewListenView Earnings Details
2/24/2015Q314($0.53)($0.47)$18.05 million$18.70 millionViewListenView Earnings Details
11/5/2014Q3($0.49)($0.46)$15.60 million$16.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.50)($0.49)$13.39 million$14.50 millionViewN/AView Earnings Details
5/7/2014Q114($0.48)($0.44)$11.33 million$11.45 millionViewN/AView Earnings Details
2/25/2014Q413($0.43)($0.48)$9.01 million$9.66 millionViewN/AView Earnings Details
11/6/2013($0.51)($3.51)$6.92 million$8.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Foundation Medicine (NASDAQ:FMI)
Current Year EPS Consensus Estimate: $-4.32 EPS
Next Year EPS Consensus Estimate: $-3.7 EPS


Dividend History for Foundation Medicine (NASDAQ:FMI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Foundation Medicine (NASDAQ:FMI)
Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 31.50%
Insider Trades by Quarter for Foundation Medicine (NASDAQ:FMI)
Institutional Ownership by Quarter for Foundation Medicine (NASDAQ:FMI)
Insider Trades by Quarter for Foundation Medicine (NASDAQ:FMI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/2/2017Jason RyanCFOSell5,573$40.00$222,920.00View SEC Filing  
6/1/2017David DalyInsiderSell555$38.30$21,256.50View SEC Filing  
4/18/2017Jason RyanCFOSell503$34.55$17,378.65View SEC Filing  
4/18/2017Steven J KafkaCOOSell4,405$34.55$152,192.75View SEC Filing  
4/3/2017David DalyInsiderSell2,070$31.96$66,157.20View SEC Filing  
4/3/2017Michael J. PelliniDirectorSell1,700$31.96$54,332.00View SEC Filing  
4/3/2017Robert W. HessleinSVPSell1,233$31.96$39,406.68View SEC Filing  
4/3/2017Steven J. KafkaCOOSell2,157$31.96$68,937.72View SEC Filing  
3/16/2017Jason RyanCFOSell12,500$31.68$396,000.00View SEC Filing  
3/16/2017Robert W HessleinSVPSell6,231$31.67$197,335.77View SEC Filing  
3/8/2017Michael J PelliniDirectorSell40,000$34.30$1,372,000.00View SEC Filing  
2/8/2017Steven J KafkaCOOSell10,415$23.24$242,044.60View SEC Filing  
1/13/2017Jason RyanCFOSell1,777$19.00$33,763.00View SEC Filing  
1/4/2017David DalyInsiderSell5,097$17.91$91,287.27View SEC Filing  
1/4/2017Jason RyanCFOSell4,665$17.74$82,757.10View SEC Filing  
1/4/2017Michael J. PelliniCEOSell14,637$17.67$258,635.79View SEC Filing  
1/4/2017Robert W. HessleinSVPSell4,682$17.74$83,058.68View SEC Filing  
1/4/2017Steven J. KafkaCOOSell8,390$17.72$148,670.80View SEC Filing  
12/1/2016David DalyInsiderSell564$19.95$11,251.80View SEC Filing  
11/22/2016Steven J KafkaCOOSell6,273$23.01$144,341.73View SEC Filing  
10/20/2016Jason RyanCFOSell506$22.45$11,359.70View SEC Filing  
10/20/2016Steven J KafkaCOOSell4,427$23.00$101,821.00View SEC Filing  
10/4/2016David DalyInsiderSell2,045$23.65$48,364.25View SEC Filing  
10/4/2016Michael J. PelliniCEOSell2,629$23.65$62,175.85View SEC Filing  
10/4/2016Robert W. HessleinSVPSell1,220$23.65$28,853.00View SEC Filing  
10/4/2016Steven J. KafkaCOOSell2,135$23.62$50,428.70View SEC Filing  
9/20/2016Steven J KafkaCOOSell9,469$23.70$224,415.30View SEC Filing  
8/19/2016Jason RyanCFOSell13,863$23.92$331,602.96View SEC Filing  
7/5/2016David DalyInsiderSell5,008$17.76$88,942.08View SEC Filing  
7/5/2016Jason RyanCFOSell4,687$17.63$82,631.81View SEC Filing  
7/5/2016Michael J. PelliniCEOSell10,160$17.63$179,120.80View SEC Filing  
7/5/2016Robert W. HessleinSVPSell4,705$17.62$82,902.10View SEC Filing  
7/5/2016Steven J. KafkaCOOSell6,495$17.67$114,766.65View SEC Filing  
6/3/2016David DalyInsiderSell472$21.66$10,223.52View SEC Filing  
4/1/2016Steven J KafkaCOOSell124$18.08$2,241.92View SEC Filing  
4/1/2016Vincent A MillerInsiderSell356$18.08$6,436.48View SEC Filing  
12/1/2015David DalyInsiderSell2,559$16.78$42,940.02View SEC Filing  
11/13/2015Michael J PelliniCEOBuy9,100$16.43$149,513.00View SEC Filing  
6/15/2015Krishna YeshwantDirectorSell183,860$32.98$6,063,702.80View SEC Filing  
4/7/2015Alexis BorisyDirectorSell234,542$50.00$11,727,100.00View SEC Filing  
4/7/2015Roche Holdings IncInsiderBuy15,604,288$50.00$780,214,400.00View SEC Filing  
4/7/2015Rock Ventures Lp ThirdMajor ShareholderSell3,976,278$50.00$198,813,900.00View SEC Filing  
3/5/2015Michael J PelliniCEOSell153,300$47.24$7,241,892.00View SEC Filing  
1/15/2015Steven J KafkaCOOSell15,000$48.38$725,700.00View SEC Filing  
1/12/2015Michael J PelliniCEOSell22,500$51.07$1,149,075.00View SEC Filing  
1/12/2015Robert W HessleinSVPSell7,000$52.11$364,770.00View SEC Filing  
1/12/2015Steven J KafkaCOOSell8,000$51.83$414,640.00View SEC Filing  
1/12/2015Vincent A MillerInsiderSell2,000$53.03$106,060.00View SEC Filing  
1/8/2015Robert W HessleinSVPSell4,000$23.03$92,120.00View SEC Filing  
12/29/2014Michael J PelliniCEOSell12,500$23.91$298,875.00View SEC Filing  
11/17/2014Jason RyanSVPSell3,541$24.90$88,170.90View SEC Filing  
11/14/2014Michael J PelliniCEOSell12,500$24.91$311,375.00View SEC Filing  
10/27/2014Jason RyanSVPSell2,360$25.00$59,000.00View SEC Filing  
10/27/2014Steven J KafkaCOOSell10,000$25.31$253,100.00View SEC Filing  
9/15/2014Jason RyanSVPSell2,361$21.92$51,753.12View SEC Filing  
8/18/2014Michael J PelliniCEOSell12,500$25.29$316,125.00View SEC Filing  
7/22/2014Steven J KafkaCOOSell10,000$27.14$271,400.00View SEC Filing  
7/15/2014Jason RyanSVPSell3,541$27.22$96,386.02View SEC Filing  
7/15/2014Vincent A MillerInsiderSell15,000$27.25$408,750.00View SEC Filing  
7/8/2014Robert W HessleinSVPSell4,000$27.22$108,880.00View SEC Filing  
7/2/2014Michael J PelliniCEOSell15,000$27.42$411,300.00View SEC Filing  
6/26/2014Jason RyanSVPSell1,180$25.00$29,500.00View SEC Filing  
6/26/2014Steven J KafkaCOOSell5,000$25.19$125,950.00View SEC Filing  
6/19/2014Steven J KafkaCOOSell5,000$24.46$122,300.00View SEC Filing  
6/16/2014Jason RyanSVPSell2,361$22.61$53,382.21View SEC Filing  
6/13/2014Krishna YeshwantDirectorSell1,300,000$22.40$29,120,000.00View SEC Filing  
6/5/2014Jason RyanSVPSell10,000$24.06$240,600.00View SEC Filing  
6/5/2014Steven J KafkaCOOSell4,500$24.19$108,855.00View SEC Filing  
5/6/2014Vincent MillerInsiderSell3,000$30.00$90,000.00View SEC Filing  
4/16/2014Jason RyanSVPSell3,541$26.36$93,340.76View SEC Filing  
4/16/2014Vincent MillerInsiderSell30,000$26.86$805,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Foundation Medicine (NASDAQ:FMI)
Latest Headlines for Foundation Medicine (NASDAQ:FMI)
DateHeadline logoBidaskClub Downgrades Foundation Medicine, Inc. (FMI) to Buy - June 17 at 6:02 PM logoETFs with exposure to Foundation Medicine, Inc. : June 16, 2017 - June 16 at 5:56 PM logo-$1.08 EPS Expected for Foundation Medicine, Inc. (FMI) This Quarter - June 16 at 8:24 AM logoFoundation Medicine, Inc. :FMI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 - June 14 at 6:27 PM logoUS genomic cancer profiling firm FMI heading for China, where access to new therapies lags - June 13 at 11:29 AM logoUS genomic cancer profiling firm FMI heads to China, where access to new therapies lags - June 13 at 11:29 AM logoASCO and Foundation Medicine Announce Collaboration to Help Research Sites Identify Potential Participants for the ... - Business Wire (press release) - June 9 at 10:29 AM logoEarnings Highlights and Review: Agilent Revenue Gained 8%; GAAP EPS Soared 79% - June 9 at 10:29 AM logoASCO and Foundation Medicine Announce Collaboration to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR) Study - June 8 at 6:15 PM logoFoundation Medicine to Identify Patients Eligible for National Cancer Institute's NCI-MATCH (Molecular Analysis for ... - Business Wire (press release) - June 7 at 4:42 PM logoFoundation Medicine to Identify Patients Eligible for National Cancer Institute’s NCI-MATCH (Molecular Analysis for Therapy Choice) Study - June 7 at 11:15 AM logoFoundation Medicine Inc (FMI) CFO Jason Ryan Sells 5,573 Shares - June 6 at 7:51 PM logoInsider Selling: Foundation Medicine Inc (FMI) Insider Sells 555 Shares of Stock - June 5 at 4:40 PM logoFoundation Medicine Inc (FMI) Upgraded at ValuEngine - June 4 at 4:56 PM logoFoundation Medicine Inc (FMI) Upgraded at Zacks Investment Research - June 2 at 11:40 PM logoFoundation Medicine Inc (FMI) Given Consensus Rating of "Hold" by Brokerages - May 29 at 9:06 PM logoFoundation Medicine (FMI) And Its Collaborators to Present New Data at ASCO - - May 18 at 10:10 AM logoFoundation Medicine and Its Collaborators to Present New Data at ASCO 2017 Supporting the Integration of Comprehensive Genomic Profiling (CGP) in Personalized Clinical Care in Oncology - May 18 at 10:10 AM logoAmid The Perceived Gloom In The Hedge Fund Universe, This Hedge Fund’s Stock Picks Gained 38.8% in Q1 - May 16 at 5:11 PM logoFoundation Medicine Inc (FMI) Raised to Buy at BTIG Research - May 15 at 11:06 AM logoFoundation Medicine Inc (FMI) Issues Earnings Results, Misses Expectations By $0.29 EPS - May 11 at 3:25 PM logoEdited Transcript of FMI earnings conference call or presentation 9-May-17 8:30pm GMT - May 10 at 9:24 AM logoFoundation Medicine reports 1Q loss - May 9 at 5:21 PM logoBRIEF-Foundation Medicine announces Q1 revenue $26.3 million - May 9 at 5:06 PM logoInvestor Network: Foundation Medicine, Inc. to Host Earnings Call - May 9 at 5:06 PM logoFoundation Medicine Announces 2017 First Quarter Results and Recent Highlights - May 9 at 5:06 PM logoCommit To Buy Foundation Medicine At $32.50, Earn 21.2% Annualized Using Options - May 5 at 5:27 PM logoFoundation Medicine (FMI) Receives Media Impact Rating of 0.30 - May 4 at 8:02 PM logoZacks: Brokerages Anticipate Foundation Medicine Inc (FMI) Will Post Earnings of -$1.02 Per Share - May 4 at 1:27 AM logo$28.91 Million in Sales Expected for Foundation Medicine Inc (FMI) This Quarter - May 4 at 1:27 AM logoFoundation Medicine Inc (FMI) Given Consensus Recommendation of "Hold" by Brokerages - May 2 at 10:52 PM logoPositive News Coverage Unlikely to Impact Foundation Medicine (FMI) Share Price - May 1 at 6:56 PM logo5 Things Bristol-Myers Squibb's Management Wants You to Know - April 29 at 9:43 AM logo-$1.02 EPS Expected for Foundation Medicine Inc (FMI) This Quarter - April 28 at 7:48 AM logoFoundation Medicine (FMI) Earns Daily Coverage Optimism Rating of 0.62 - April 28 at 7:40 AM logoFoundation Medicine (FMI) Given Daily Media Sentiment Score of 0.22 - April 25 at 8:33 PM logoFoundation Medicine (FMI) Getting Positive Media Coverage, Study Shows - April 21 at 8:21 PM logoInsider Selling: Foundation Medicine Inc (FMI) CFO Sells 503 Shares of Stock - April 20 at 8:10 PM logoSteven J. Kafka Sells 4,405 Shares of Foundation Medicine Inc (FMI) Stock - April 20 at 8:09 PM logoH3 Biomedicine Extends Collaboration with Foundation Medicine to Develop Precision Therapies for Cancer - April 20 at 12:23 PM logoFoundation Medicine Announces Timing for First Quarter 2017 Financial Results and Conference Call - April 20 at 12:23 PM logoVery Favorable News Coverage Extremely Likely to Effect Foundation Medicine (FMI) Stock Price - April 17 at 12:30 PM logoFoundation Medicine (FMI) Getting Favorable Press Coverage, Report Finds - April 14 at 9:52 AM logoWhich Cancer Patients Will Be Helped By Powerful Immune Drugs? This Test May Tell - April 12 at 5:17 PM logoZacks Investment Research Upgrades Foundation Medicine Inc (FMI) to Hold - April 6 at 10:18 PM logoFoundation Medicine Inc (FMI) Lifted to "Hold" at Zacks Investment Research - April 6 at 8:07 AM logoFoundation Medicine Inc (FMI) SVP Robert W. Hesslein Sells 1,233 Shares - April 5 at 9:16 PM logoInsider Selling: Foundation Medicine Inc (FMI) Director Sells 1,700 Shares of Stock - April 5 at 9:15 PM logoFoundation Medicine Inc (FMI) COO Steven J. Kafka Sells 2,157 Shares - April 5 at 8:55 PM logoDavid Daly Sells 2,070 Shares of Foundation Medicine Inc (FMI) Stock - April 5 at 8:55 PM



Foundation Medicine (FMI) Chart for Thursday, June, 22, 2017

This page was last updated on 6/22/2017 by Staff